able us to better plan distribution of products, leading to the creation of sustainable national hemophilia care programs that are a vital part of the public health care system. We are grateful to our industry partners such as CSL Behring, who provide, among other resources, valuable and life-saving medicine, including this most recent donation of coagulation factor. We are very pleased to announce it on World Hemophilia Day 2009."
Factor VIII is an essential blood clotting factor. FVIII is concentrated from donated blood or is manufactured using recombinant technology, and can be given to hemophiliacs to restore hemostasis.
About the Global Alliance for Progress
The Global Alliance for Progress (GAP) a 10-year healthcare development project, launched in April 2003. GAP's goal is to greatly increase the diagnosis and treatment of people with hemophilia and other bleeding disorders in developing countries.
The project aims to close the gap between the number of people born with hemophilia and those who reach adulthood, the gap between the estimated and actual number of people diagnosed with bleeding disorders, and the gap between the amount of treatment product needed versus what is available.
GAP partners include CSL Behring, Baxter, Bayer, Biotest, the Irish Hemophilia Society, the Jan Willem André de la Porte Family Foundation, Talecris, the World Health Organization (WHO), and Wyeth.
Fifteen countries have participated in GAP: Armenia, Azerbaijan, Belarus, Ecuador, Egypt, Georgia, Jordan, Lebanon, Mexico, Philippines, Russia, Syria, Thailand, and Tunisia. A GAP project in China has just been launched.
About the World Federation of Hemophilia
The World Federation of Hemophilia (WFH) is an international not-for-profit organization dedicated to improving the lives of people with hemophilia and related bleeding disorders.
Since it was established in 1963, the WFH has grown into a
'/>"/>
Source: PRWeb Copyright©2009 Vocus, Inc. All rights reserved | |
Page: 1 2 3 4 Related medicine news :1.
Siemens Extends Tender Offer for Acquisition of Dade Behring2.
Siemens Announces Early Termination of Hart-Scott-Rodino Waiting Period For Acquisition of Dade Behring Holdings, Inc.; U.S. Antitrust Clearance Achieved3.
CSL Behrings Helixate(R) FS Now Available in 2000 IU Vial Size to Improve Patient Convenience, Encourage Compliance4.
Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease5.
CSL Behring Receives FDA Approval of RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency6.
CSL Behring to Launch Next GameFaces Program Challenge 7.
The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top8.
Middle School Marks Most Critical Time to Start Ongoing Conversations About Drug and Alcohol Use With Kids9.
Excerpts from DNC Chairman Howard Deans Remarks at the National Baptist Convention10.
End-to-End HR Performance Benchmarks: Metrics That Will Help Turn the HR Cost Center into a Productivity Driver11.
Health Department Marks Take a Loved One to the Doctor Day